Observational studyEndocrine2025
Effect of Roxadustat on bone metabolism markers in patients with renal anemia.
Observational study in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative effects of roxadustat and epoetin beta on lumbar trabecular BMD in dialysis patients.Journal of bone and mineral metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRoxadustat, a prolyl hydroxylase domain inhibitor that stabilizes hypoxia-inducible factor (HIF) expression, is a recently developed drug for the treatment of renal anemia. Studies have shown that HIF activation not only stimulates the production of endogenous erythropoietin but also modulates bone metabolism. Patients with chronic kidney disease (CKD) often present with abnormalities in bone metabolism in addition to concomitant anemia. However, the effect of Roxadustat on bone metabolism markers in patients with renal anemia have rarely been reported.
objective(1) To investigate the effect of Roxadustat on bone metabolism markers in patients with renal anemia; (2) To investigate the effect of Roxadustat on inflammatory and lipid metabolism markers in patients with renal anemia.
methodsThis retrospective observational study enrolled a total of 52 patients with anemia secondary to CKD, who were categorized into a roxadustat group and a control group based on whether they received roxadustat treatment. The following markers, including hemoglobin (Hb), β-C-terminal telopeptide of type I collagen (β-CTX), total type I procollagen intact N-terminal propeptide (tP1NP), parathyroid hormone (PTH), osteocalcin (OC), 25-hydroxyvitamin D (25-OHD), alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P), C-reactive protein (CRP), Procalcitonin (PCT), total cholesterol (TC), low-density lipoprotein (LDL), were measured before and after treatment. The changes of bone metabolism, inflammatory and lipid metabolism markers were compared before and after treatment.
resultsAfter a period of Roxadustat treatment, β-CTX and PTH levels were significantly lower compared to pre-treatment, while tP1NP, 25-OHD, and ALP levels increased compared to pre-treatment (P < 0.05). Inflammatory markers (PCT) and lipid metabolism markers (TC, LDL) were significantly reduced (P < 0.05). No statistically significant differences were observed in the control group.
conclusionIn this study, Roxadustat treatment for renal anemia was associated with simultaneous improvements in markers of bone metabolism, inflammation, and lipid metabolism in CKD patients.
Indexed as
Identifiers
41460382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.